
## **NINDS Repository Investigator Tracking Data Form**

Approval to submit must be renewed at least annually, ideally at the time of IRB re-approval

(A <u>) Investigator C</u>	<u>Contact Informa</u>	<u>ition:</u>		
Name:		Institution:		
Address:				
E-mail:	Phone:	Fax:		
(B) Study Coordin	<u> ator:</u>			
Name:		Institution:		
Address:				
E-mail:	Phone:	Fax:		
(C) Funding Infor	mation:			
Funded By: NINDS		snecifu):		
Grant Number:			End Date:	
Grant Principal Investigat				
(D) <u>Sample Collec</u>				
	• , .	• •	if applicable, per application	•
disorder category is to b	e banked please subr	nit a separate appl	ication (this form) for each.	
	DI	ease list all relevan	t diagnoses	
Frontotemporal Deg			-	
Parkinsonism				-
Epilepsy				_
Cerebrovascular Dise	ase			_
Motor Neuron Diseas	se			_
Tourette Syndrome				_
Dystonia				_
Huntington's Disease				_
Other (please specify		IS		_
Other (please specify				
(E) Ethnic and Ra	cial Characteri	etice		
(*Complete section <b>E</b> <u>o</u>			rudies)	
L. Ethnicity: Hispanic _			-	
			sian%; Pacific Islande	r %·
			(Race should equal 100%	
(F) Submission Ca	<del>_</del>		•	
Blood	Serum		aliva	
Skin biopsy	Cerebral Spi		Other (please specify)	
Plasma	Urine		the (picase specify)	······
	1 1 1 1 1 1 1 1 1 1			







•	_	E <b>mbargo Perioa:</b> plete section <b>G</b> <u>only</u> if submitting blood for genetic studie:	s)	
ас	epto	n aware that imposing an embargo period will be pending app able submission includes acceptable biospecimens and clinical oble, to the NINDS Repository.	•	_
		Blood for DNA Preparation Options: (select one)		
	Rele	ease immediately Release 1 year after submission	Release 2 years a	fter submission
<b>(</b> H	I) <u>S</u>	subjects and Study Information:		
1.	ls t	:his a case/control study?		
		If yes, please answer the following:		
	a.	How many cases?	Next 12 months	Entire Project
	b.	How many controls (population + spousal)?	Next 12 months	Entire Project
2.	ls t	chis a family-based study?		
		If yes, please answer the following:		
	a.	Describe family structure used to identify families for study (e.g. parents & affected child; sibling pairs; extended family) <i>Please</i>		
	b.	Total number of <u>affected</u> individuals to be ascertained: <b>(DO N</b> )	OT INCLUDE CASE/CO	NTROL INFO LISTED ABOVE)
			Next 12 months	Entire Project
	c.	Total number of <u>unaffected</u> family members to be ascertained	:	
			Next 12 months	Entire Project
3.	-	you checked Yes for both 1 and 2 above, list the total number or $a+2.b$ )	of <u>affected</u> subjects pa	articipating in the study.
	•	•	Next 12 months	Entire Project
4.	-	our study does not fit either of the categories above, please de omitted?	escribe and enumerat	te the subjects that will be
	a.	How many cases?	Next 12 months	Entire Project
		Please describe these individuals		
	b.	How many non-cases?	Next 12 months	Entire Project
		Please describe these individuals		
If y	es, p	this study part of a clinical trial? Yes No lease describe study design, therapeutic intervention (if applicable), no spic/clinical information, to be obtained (attach separate sheet).	umber of subjects, lengt	h of trial and additional








(I)	Overview of deficite information for biospecimens.				
1.	Known genetic information <b>prior</b> to sample ascertainment:				
	a. Known genetic syndrome: Present Absent Unknown				
	(If tested, please specify known genetic syndrome)				
	<b>b.</b> Known mutations or genetic variance in DNA: Present Absent Unknown				
	(If tested, please specify known mutations)				
2.	Will the samples be screened for known mutations: Yes No				
	If yes, please indicate mutations to be screened:				
	Once confirmed, I will submit data on all known mutations for every submission and how each is associated with any dbGaP data. <i>(REQUIRED FOR APPROVAL)</i>	า sample			
<b>(</b> 1)	Submitter Benefits:				
	, · blood submissions that are subject to DNA extractions, you are entitled to 20μg of DNA per unique submiss	sion			
	epted for clinical data. For skin biopsy submissions, you are entitled to 1 ampoule of fibroblasts per unique				
sub	omission accepted for clinical data.				
Ple	ase indicate your preference (select one)				
1.	Please send to PI or Study Coordinator. (please specify)				
	If shipping address differs from that listed on pg. 1 of this form, please provide below.				
	Name:				
	Shipping Address:				
	Email: Phone:				
2.	Please send to a collaborator.				
	If you checked 2 please provide info below.				
	Name:				
	Shipping Address:				
	Email: Phone:				
	If you checked 1 or 2 please be aware that DNA will be shipped in batches of at least 10.				
3.	Please store to be requested at a later date.				
۶. 4.	I elect to forego the opportunity to receive back-in-kind samples.				
		0 110doz			
5.	I am submitting under a Biomarkers program, DNA will be stored until a later date and my benefits are the discretion of NINDS.	: under			







	(K) Please acknowledge all of the following:
1.	☐ I have received IRB approval to submit samples to the NINDS Repository.
	COPY OF YOUR APPROVED CONSENT MUST ACCOMPANY THIS REQUEST.
2.	I am submitting from a site in the United States or Canada and I will transfer CDE information to Coriell electronically using the Repository's electronic data entry system, as required, when the sample is submitted.
	Or  I am submitting from a site outside the United States or Canada and I elect to transfer CDE information to Coriell using the Repository's electronic data entry system.
	Or  This is a large project and I would like to utilize an alternative electronic data transfer system that is custom-designed for my project.
	Or .
	Submission of clinical data is <u>not required</u> by my study, as agreed to by NINDS.
3.	☐ I am aware that to promote sharing I am required to report all publications which refer to a given sample or sample set from the NINDS Repository when published, noting sample or catalog numbers in the publications (send email to <a href="mailto:ninds@coriell.org">ninds@coriell.org</a> ).
4.	I acknowledge and agree that my submissions can be distributed according to the terms and conditions of the NINDS Repository MTA. https://catalog.coriell.org/0/Sections/Support/NINDS/assurance.aspx?PgId=307
5.	☐ I agree to share protocols for sample preparation if requested by the NINDS Repository
	(*Complete ( and 7 only if any horitting blood for you stip studies)
6.	(*Complete 6 and 7 <u>only</u> if submitting blood for genetic studies)  I will not submit duplicate subjects/samples from my study or other studies.
7.	I have reviewed the Submitter's Guide and the Frequently Asked Questions (FAQs) section of the NINDS
•	Repository Website; see https://catalog.coriell.org/1/NINDS/Additional-Resources/Submitters-Guide
<u>O</u> j	Dtional: I would like to be listed on the website Acknowledgment Page as a submitter to the NINDS Repository. <a href="https://catalog.coriell.org/0/Sections/Collections/NINDS/Contributors.aspx?PgId=188&amp;coll=ND">https://catalog.coriell.org/0/Sections/Collections/NINDS/Contributors.aspx?PgId=188&amp;coll=ND</a>
Ву	signing below, I agree to abide by the regulations of the NINDS Repository.
	Submit to: NINDS Repository
Siq	nature, Principal Investigator Date NINDS@coriell.org
_	Fax: 856-966-5067
	If you have any questions about this form places contact a Project Manager at hinds@coriell.org
	If you have any questions about this form please contact a Project Manager at <a href="mailto:ninds@coriell.org">ninds@coriell.org</a> .





